“The extensive marketing and product management experience in the life sciences research market of Drs. Redpath and Somasundaram, particularly in the cellular bioassay and analysis markets, will accelerate the commercialization of Cyntellect’s products for applications in biopharmaceutical cell line development, cell line development for drug discovery and research, and key applications utilizing stem cells and primary cells and for Cell Health applications,” said David Burns, Cyntellect’s VP Sales & Marketing and Chief Operating Officer. “We are very pleased to add the caliber and extensive experience of both Stella and Baggi to the Cyntellect commercial team.”
Prior to joining Cyntellect, Dr. Redpath was a senior marketing manager at Millipore Corporation, where she led the predictive toxicology and high content analysis programs. She has also held business and sales positions at GE Healthcare, in the Advanced Systems Business Unit, and at Ciphergen Biosystems where she was Instrumentation Product Manager. Dr. Redpath was a Research Fellow in the Department of Immunology at the Scripps Research Institute (TSRI), and earned a Ph.D in Molecular Immunology in 1996 from the University of Cambridge, UK.
Prior to joining Cyntellect, Dr. Somasundaram was a Product Manager at BD Biosciences, where he managed the high content and confocal imaging platforms. He has also held business manager and sales positions at Atto Biosciences, and at PerkinElmer where he was the Applications Manager Live Cell Confocal Imaging Platform. Dr. Somasundaram was a Senior Research Fellow in the Department of Physiology, University of Cambridge, UK and at the Babraham Institute, Cambridge, and earned a Ph.D from the University of Wales, UK.
About Cyntellect
Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company’s web site at www.cyntellect.com.
